Minghui Pharmaceutical Announces Strategic Partnership and Licensing Agreement with Qilu Pharmaceutical to Develop B7-H3 ADC in Greater China
SHANGHAI, May 9, 2025 /PRNewswire/ — Minghui Pharmaceutical (“Minghui”), a late-stage clinical biopharmaceutical company, today announced an exclusive licensing and collaboration agreement with Qilu Pharmaceutical (“Qilu”) for the development, manufacturing, and commercialization of its B7-H3 ADC (MHB088C) in Greater China (including Mainland China, Hong Kong, Macau, and Taiwan). Under the agreement, Qilu will obtain exclusive rights […]